AR122463A2 - Suspensiones de nanopartículas que contienen polímero de carboxivinilo - Google Patents

Suspensiones de nanopartículas que contienen polímero de carboxivinilo

Info

Publication number
AR122463A2
AR122463A2 ARP210101199A ARP210101199A AR122463A2 AR 122463 A2 AR122463 A2 AR 122463A2 AR P210101199 A ARP210101199 A AR P210101199A AR P210101199 A ARP210101199 A AR P210101199A AR 122463 A2 AR122463 A2 AR 122463A2
Authority
AR
Argentina
Prior art keywords
carboxyvinyl polymer
concentration
compound
soluble particulate
galactomannan
Prior art date
Application number
ARP210101199A
Other languages
English (en)
Inventor
Masood A Chowhan
Malay Ghosh
Bahram Asgharian
Wesley Wehsin Han
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43425837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR122463(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR122463A2 publication Critical patent/AR122463A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las composiciones de suspensión poseen un polímero de carboxivinilo tal como un carbómero, un galactomanano tal como guar, y un compuesto borato. Un compuesto particulado moderadamente soluble tal como nepafenac también se incluye en las composiciones. El compuesto particulado moderadamente soluble posee un tamaño de particular pequeño para aumentar la biodisponibilidad del compuesto. Reivindicación 1: Una composición de suspensión oftálmica acuosa que se administra de modo tópico caracterizada porque comprende: un polímero de carboxivinilo en una concentración de 0,1 a 0,5% p/v; un galactomanano en una concentración de 0,1 a 0,4% p/v; borato en una concentración de 0,4 a 2,0% p/v; y un compuesto particulado moderadamente soluble, que posee una solubilidad en agua a 25ºC de 0,001 a 0,1% p/v y un tamaño de partícula de 50 a 700 nm. Reivindicación 14: Una composición de acuerdo con la reivindicación 1, caracterizada porque dicho polímero de carboxivinilo es carbómero, dicho galactomanano es guar, dicho borato es ácido bórico, y dicho compuesto particulado moderadamente soluble es nepafenac a una concentración de 0,1 hasta 1,0% p/v.
ARP210101199A 2009-12-03 2021-05-03 Suspensiones de nanopartículas que contienen polímero de carboxivinilo AR122463A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26636809P 2009-12-03 2009-12-03

Publications (1)

Publication Number Publication Date
AR122463A2 true AR122463A2 (es) 2022-09-14

Family

ID=43425837

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP100104470A AR080572A1 (es) 2009-12-03 2010-12-03 Suspensiones de nanoparticulas que contienen polimero de carboxivinilo
ARP210101199A AR122463A2 (es) 2009-12-03 2021-05-03 Suspensiones de nanopartículas que contienen polímero de carboxivinilo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP100104470A AR080572A1 (es) 2009-12-03 2010-12-03 Suspensiones de nanoparticulas que contienen polimero de carboxivinilo

Country Status (27)

Country Link
US (3) US8921337B2 (es)
EP (3) EP2965749B1 (es)
JP (3) JP5864433B2 (es)
KR (2) KR101543613B1 (es)
CN (1) CN102724965B (es)
AR (2) AR080572A1 (es)
AU (1) AU2010326099B2 (es)
BR (1) BR112012013503B8 (es)
CA (1) CA2781254C (es)
CL (1) CL2012001402A1 (es)
CY (1) CY1120585T1 (es)
DK (3) DK2506831T3 (es)
ES (3) ES2684752T3 (es)
HK (3) HK1170164A1 (es)
HR (2) HRP20140016T1 (es)
HU (2) HUE025838T2 (es)
LT (1) LT2965749T (es)
MX (1) MX2012006231A (es)
PL (3) PL2965749T3 (es)
PT (3) PT2965749T (es)
RS (2) RS53085B (es)
RU (1) RU2571078C2 (es)
SI (3) SI2965749T1 (es)
TW (1) TWI486178B (es)
UY (1) UY33081A (es)
WO (1) WO2011068872A2 (es)
ZA (1) ZA201203770B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435631B2 (en) * 2010-04-15 2013-05-07 Ppg Industries Ohio, Inc. Microporous material
MX347598B (es) * 2010-07-20 2017-05-03 C-Ip S A * Suspension de compuesto que contiene boro.
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
US20160051503A1 (en) * 2012-08-31 2016-02-25 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac
US20150191647A1 (en) * 2014-01-07 2015-07-09 Trican Well Service Ltd. Stability of viscous fluids in low salinity environments
PT3721868T (pt) 2015-01-26 2022-08-12 Bausch & Lomb Composição para suspensão oftálmica
CN108367026A (zh) * 2015-06-18 2018-08-03 常规制药股份公司 抗微生物配制品
TW201938141A (zh) * 2018-02-21 2019-10-01 瑞士商諾華公司 基於脂質的眼用乳劑
US11730699B2 (en) 2018-02-21 2023-08-22 Alcon Inc. Lipid-based ophthalmic emulsion

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864183A (en) * 1972-11-21 1975-02-04 Tokyo Hat Method for producing pen core from filament tows
US4313949A (en) 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5461081A (en) 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
FR2761959B1 (fr) * 1997-04-15 1999-05-21 Oreal Ensemble de conditionnement et d'application d'un produit fluide
CN1229110C (zh) * 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
IT1306123B1 (it) 1999-04-02 2001-05-30 Technopharma Sa Soluzione oftalmica viscosizzata con azione detergente sulle lenti acontatto.
ITMI991453A1 (it) 1999-07-01 2001-01-01 Farmila Farma Milano Composizioni oftalmiche in forma di gel acquosi
CA2395331C (en) 1999-12-23 2009-01-06 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
TNSN03137A1 (en) 2001-06-22 2005-12-23 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS.
EP1448209A2 (en) 2001-10-23 2004-08-25 Ranbaxy Laboratories, Ltd. A process for the preparation of pharmaceutical compositions for topical delivery of cyclooxygenase-2 enzyme inhibitors
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
AU2003213210A1 (en) 2002-02-22 2003-09-09 Pharmacia Corporation Ophthalmic formulation with gum system
US7947295B2 (en) 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
ATE444732T1 (de) 2003-08-07 2009-10-15 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
FR2865648B1 (fr) 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20080145430A1 (en) 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
TWI393567B (zh) 2005-03-31 2013-04-21 Bausch & Lomb 治療乾眼之組合物及相關之製造方法及使用方法
JP4257860B2 (ja) * 2005-04-19 2009-04-22 中得工業株式会社 化粧材の塗布具
CA2607014A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
ES2322200T3 (es) 2005-05-10 2009-06-17 Alcon, Inc. Formulaciones en suspension que comprenden un principio activo, un tensioactivo poloxamero o meroxapol y un glicol, su uso para la fabricacion de un medicamento para tratar trastornos oftalmicos.
US20060292203A1 (en) 2005-06-08 2006-12-28 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
JP5112669B2 (ja) 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
WO2007058935A2 (en) 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20070299124A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
US20080039398A1 (en) 2006-01-25 2008-02-14 Ousler George W Iii Formulations and methods for treating dry eye
EP1981491A4 (en) 2006-01-25 2009-09-23 Aciex Inc COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DROUGHT
US20080181957A1 (en) 2006-06-23 2008-07-31 Min Wei Increased amorphous stability of poorly water soluble drugs by nanosizing
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
JP2010528014A (ja) 2007-05-24 2010-08-19 アーシエックス セラピューティックス， インコーポレイテッド ドライアイを処置するための処方物および方法
BRPI0910717A2 (pt) * 2008-04-26 2015-09-29 Alcon Res Ltd sistema polimérico de lágrima artificial
JP4395189B1 (ja) * 2008-08-29 2010-01-06 株式会社ソリトン 塗布具
KR20110113199A (ko) 2009-02-05 2011-10-14 알콘 리서치, 리미티드 구아의 정제 방법
JP5716960B2 (ja) * 2011-05-23 2015-05-13 オーベクス株式会社 塗布体用素材の製造方法及び塗布体用素材並びに塗布体及び塗布具

Also Published As

Publication number Publication date
HK1178802A1 (en) 2013-09-19
US20110135743A1 (en) 2011-06-09
JP6055849B2 (ja) 2016-12-27
TW201129395A (en) 2011-09-01
US20170020818A1 (en) 2017-01-26
CA2781254A1 (en) 2011-06-09
WO2011068872A3 (en) 2012-01-12
AU2010326099B2 (en) 2013-03-07
PT2965749T (pt) 2018-10-09
TWI486178B (zh) 2015-06-01
HRP20140016T1 (hr) 2014-01-31
BR112012013503B8 (pt) 2021-05-25
CA2781254C (en) 2016-06-28
HUE038821T2 (hu) 2018-11-28
US20150072011A1 (en) 2015-03-12
HUE025838T2 (en) 2016-04-28
MX2012006231A (es) 2012-07-03
JP2013512912A (ja) 2013-04-18
JP5864433B2 (ja) 2016-02-17
ES2684752T3 (es) 2018-10-04
SI2586426T1 (sl) 2015-11-30
HK1170164A1 (en) 2013-02-22
DK2586426T3 (en) 2015-11-23
EP2965749A1 (en) 2016-01-13
WO2011068872A8 (en) 2013-04-04
CN102724965A (zh) 2012-10-10
CY1120585T1 (el) 2019-07-10
UY33081A (es) 2011-04-29
PL2586426T3 (pl) 2016-01-29
DK2506831T3 (da) 2013-12-16
JP2015061886A (ja) 2015-04-02
JP2016106155A (ja) 2016-06-16
BR112012013503B1 (pt) 2021-04-20
US8921337B2 (en) 2014-12-30
HK1217091A1 (zh) 2016-12-23
EP2586426A1 (en) 2013-05-01
WO2011068872A2 (en) 2011-06-09
KR101543613B1 (ko) 2015-08-11
PL2506831T3 (pl) 2014-05-30
RS57465B1 (sr) 2018-09-28
US9662398B2 (en) 2017-05-30
LT2965749T (lt) 2018-08-10
RU2012127675A (ru) 2014-01-20
SI2506831T1 (sl) 2014-01-31
RU2571078C2 (ru) 2015-12-20
PT2586426E (pt) 2015-11-17
EP2506831A2 (en) 2012-10-10
CL2012001402A1 (es) 2014-03-28
KR101809484B1 (ko) 2017-12-15
EP2586426B1 (en) 2015-09-23
KR20150063587A (ko) 2015-06-09
ES2550942T3 (es) 2015-11-13
PL2965749T3 (pl) 2018-10-31
HRP20181337T1 (hr) 2018-10-19
BR112012013503A2 (pt) 2016-06-07
RS53085B (en) 2014-06-30
PT2506831E (pt) 2014-01-08
ZA201203770B (en) 2013-08-28
SI2965749T1 (sl) 2018-09-28
DK2965749T3 (en) 2018-08-27
AR080572A1 (es) 2012-04-18
ES2441420T3 (es) 2014-02-04
EP2965749B1 (en) 2018-05-23
CN102724965B (zh) 2015-08-05
AU2010326099A1 (en) 2012-07-19
KR20120099269A (ko) 2012-09-07
EP2506831B1 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
AR122463A2 (es) Suspensiones de nanopartículas que contienen polímero de carboxivinilo
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
AR122746A2 (es) Una formulación farmacéutica líquida estable de anticuerpo
BR112012026338A2 (pt) novos derivados de 3,3-dimetil tetrahidroquinolina
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
MX2014013315A (es) Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
NZ628398A (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
EP2528602A4 (en) FORMULAS FROM BENDAMUSTIN
BR112012013847A2 (pt) novos derivados de indolinona ciclopropano
NI201500073A (es) Dispersión sólida con solubilidad mejorada que comprende un derivado de tetrazol como ingrediente activo.
DOP2012000281A (es) Composiciones farmaceuticas y metodos para su elaboracion
BR112013028449A2 (pt) composições compreendendo partículas de hidrogel
BR112014006248A2 (pt) compostos de triazolopiridina como inibidores de pde10a
PH12014501937A1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
AR094012A1 (es) Composiciones estables con peroxido para el cuidado oral
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
BR112015009603A2 (pt) novos derivados de pirazina
PE20130374A1 (es) Composicion farmaceutica que comprende ibuprofeno
EA201490573A1 (ru) Соединение бензотиазолона
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
AR101060A1 (es) Conjugados de fviii
CY1122694T1 (el) Φαρμακοτεχνικη μορφη η οποια περιεχει κουρκουμινη
EA201370198A1 (ru) КЛАТРАТНЫЕ КОМПЛЕКСЫ β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ (ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, ОБЛАДАЮЩИЕ ПРОТИВОВИРУСНЫМ ДЕЙСТВИЕМ, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
BR112015010469A2 (pt) derivados de imidazopiridina
CN105519579A (zh) 一种煤矿巷道用消毒剂